SLC6A3

SLC6A3 (DAT) is the plasma membrane dopamine reuptake transporter, and its transport activity and surface availability are dynamically governed by N-terminal phosphorylation: site-directed mutagenesis maps PKC (S7), PI3K (T62, S581, T612), and MEK1/2 (S12, T595) phosphoacceptor residues that control surface expression and dopamine uptake Vmax (PMID:12660249). Beyond reuptake, DAT can run in reverse — activation of Gq-coupled receptors drives PKC-dependent DAT-mediated dopamine efflux (PMID:20477913). Surface trafficking is further shaped by the GDNF/Ret signaling axis, in which the Rho-family GEF Vav2 is required to regulate DAT surface expression and transport selectively in nucleus accumbens dopamine terminals (PMID:26147533). DAT operates within physical complexes: it associates with D2 receptors, whose interaction controls DAT surface expression and protects dopaminergic neurons from dopamine neurotoxicity (PMID:28579325), and with Kv7.2/7.3 potassium channels, which co-cluster with DAT and readjust membrane potential during transport (PMID:30885609). The autism/ADHD-associated coding variant A559V is hyper-phosphorylated, displays constitutively elevated PKCβ activity, resists amphetamine-induced trafficking, and supports anomalous dopamine efflux that is reversed by PKCβ inhibition or N-terminal serine substitution (PMID:25313507); in knock-in mice this variant remodels cocaine responses through SERT and 5-HT2C receptor signaling (PMID:30578419). At the transcriptional level, the 3'-UTR VNTR acts as an enhancer in dopamine neurons (PMID:11739616), and 5' promoter haplotypes/SNPs modulate DAT expression with associations to Parkinson's disease and schizophrenia risk (PMID:16963468, PMID:26707863). DAT is also expressed and transport-active outside the nervous system, including renal carcinoma cells under HIF-2α control (PMID:27663598), blood platelets (PMID:16490314), and sperm (PMID:25402186).

1. 2001 Medium

   Established that non-coding regulatory architecture of SLC6A3 controls its transcription in the relevant cell type, framing DAT level as a genetically tunable variable in dopamine neurons.

   Evidence Reporter assays of the 3'-UTR 9-repeat VNTR via lipid and biolistic transfection in dopaminergic cell lines and primary midbrain neurons

   PMID:11739616

   Open questions at the time

   • Does not identify the trans-acting factors binding the VNTR
   • Enhancer activity in immortalized/primary cells may not reflect in vivo expression magnitude
2. 2003 High

   Resolved how DAT activity is post-translationally controlled by mapping distinct N-terminal phosphoacceptor sites to specific kinase cascades, defining the molecular substrate for activity regulation.

   Evidence Mutagenesis of 20 N-terminal sites with kinase inhibitors/activators, dopamine uptake assays, and 32P-labeling

   PMID:12660249

   Open questions at the time

   • Performed in heterologous expression, not native dopamine terminals
   • Does not establish the trafficking machinery downstream of phosphorylation
3. 2010 High

   Showed DAT can function in reverse, linking Gq/PKC signaling to dopamine efflux and establishing the transporter as a bidirectional, signal-regulated conduit.

   Evidence Amperometry in rat substantia nigra slices and HPLC in cells with Gq-receptor and PKC pharmacology

   PMID:20477913

   Open questions at the time

   • Does not identify which N-terminal PKC site mediates efflux in this context
   • Physiological trigger for endogenous Gq-driven efflux unclear
4. 2015 High

   Placed DAT surface regulation within an in vivo GDNF/Ret/Vav2 signaling pathway with regional specificity, connecting extracellular trophic signaling to transporter availability and behavior.

   Evidence Vav2-/- and Ret-/- knockout mice with DAT surface assays, dopamine measurements, and cocaine behavior

   PMID:26147533

   Open questions at the time

   • Molecular link between Vav2 GEF activity and DAT trafficking not resolved
   • Restricted to nucleus accumbens terminals; striatal generality untested
5. 2017 Medium

   Demonstrated that the D2R–DAT physical complex regulates DAT surface expression and modulates dopamine neurotoxicity, defining a receptor-transporter functional unit.

   Evidence Interfering peptide (DAT-S1) disruption with surface expression, caspase-3/PARP-1 cleavage, and neurotoxicity assays

   PMID:28579325

   Open questions at the time

   • Interface residues mediating the complex not mapped
   • Neuroprotection shown in model system, not in vivo disease context
6. 2019 Medium

   Identified Kv7.2/7.3 channels as DAT partners that couple transport-associated depolarization to membrane potential recovery, linking electrogenic transport to channel activity.

   Evidence BioID, reciprocal Co-IP in HEK293, co-transfection imaging in neurons, uptake assays, and electrophysiology

   PMID:30885609

   Open questions at the time

   • Stoichiometry and direct interface of the DAT–Kv7 complex unknown
   • In vivo functional consequence of the coupling untested
7. 2014 High

   Connected a disease coding variant (A559V) to dysregulated PKCβ-dependent trafficking and anomalous efflux, providing a mechanistic basis for transporter dysfunction in neuropsychiatric disease.

   Evidence Surface biotinylation/trafficking, PKCβ activity assays, N-terminal serine mutagenesis, and efflux measurements in transfected cells

   PMID:25313507

   Open questions at the time

   • Mechanism by which A559V constitutively activates PKCβ unresolved
   • Heterologous-cell findings require native-neuron confirmation
8. 2018 Medium

   Revealed that the A559V variant remodels psychostimulant responses through SERT and 5-HT2C signaling independent of striatal DA release, broadening the circuit-level consequences of a DAT variant.

   Evidence DAT Val559 knock-in mice with fluoxetine/5-HT2C/RTI-113 pharmacology, locomotor assays, and DA microdialysis

   PMID:30578419

   Open questions at the time

   • How a DAT variant engages serotonergic signaling mechanistically is unexplained
   • Single knock-in line, single lab
9. 2006 Medium

   Functional promoter haplotype variation under balancing selection was linked to DAT transcriptional activity and Parkinson's disease risk with gene-environment interaction, extending regulatory control to disease susceptibility.

   Evidence Haplotype reporter transfection in dopaminergic cells, population genetics, and case-control gene-environment association

   PMID:16963468

   Open questions at the time

   • Causal SNP within haplotype clades not isolated
   • Association does not establish DAT level as the disease driver
10. 2015 Medium

    Linked elevated nigral DAT mRNA to schizophrenia risk and provided a functional promoter SNP (rs1478435) mechanism, reinforcing transcriptional dosage as a disease-relevant axis.

    Evidence Postmortem qPCR in nigral DA neurons, promoter-reporter assay, and case-control association

    PMID:26707863

    Open questions at the time

    • Direction of causality between DAT expression and disease unproven
    • Other promoter elements not surveyed
11. 2016 Medium

    Showed DAT is functionally expressed outside the nervous system and is transcriptionally controlled by HIF-2α in renal carcinoma, indicating a hypoxia-regulated context for transporter expression.

    Evidence [3H]-dopamine uptake, HIF-1α/HIF-2α siRNA knockdown, and hypoxia treatment in ccRCC cells

    PMID:27663598

    Open questions at the time

    • Biological role of dopamine uptake in renal cancer unclear
    • Direct vs indirect HIF-2α regulation of SLC6A3 not distinguished
12. 2019 Low

    Proposed that atypical DAT inhibitors act as pharmacochaperones rescuing ER-retained misfolded DAT to the surface, linking inhibitor binding mode to folding correction.

    Evidence Mechanistic synthesis of pharmacochaperoning and ER retention/surface expression experiments (review)

    PMID:31064865

    Open questions at the time

    • Review without primary data in this entry
    • Structural basis of chaperone binding to folding intermediates not directly demonstrated here

• How phosphorylation, trophic signaling, and the D2R/Kv7 complexes are integrated to set DAT surface density and direction of transport in native dopamine terminals remains unresolved.
• No unified structural/biochemical model linking N-terminal phosphosites to specific trafficking machinery
• Interfaces of DAT physical complexes not mapped
• In vivo causal contribution of transcriptional variants to disease unestablished